The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia-Reference-Cited by-同舟云学术

The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia

Published:2000-02 Issue:4 Volume:25 Page:411-417
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Byrne JL,Stainer C,Cull G,Haynes AP,Bessell EM,Hale G,Waldmann H,Russell NH

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1702165.pdf

Reference50 articles.

1. Thomas E . Marrow transplantation for malignant diseases J Clin Oncol 1983 1: 517–521

2. Thomas E, Clift R, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia Ann Intern Med 1986 104: 155–163

3. Goldman J, Apperley J, Jones L et al. Bone marrow transplantation for patients with chronic myeloid leukemia New Engl J Med 1986 314: 202–207

4. Beatty P, Dahlberg S, Milford E . Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor Transplantation 1995 52: 778–782

5. Goldman J for the WMDA Executive Committee . A special report: bone marrow transplants using volunteer donors – recommendations and requirements for a standardised practice throughout the world – 1994 update Blood 1994 84: 2833–2839

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harvest Quality, Nucleated Cell Dose and Clinical Outcomes in Bone Marrow Transplantation: A Retrospective Study;Transplantation and Cellular Therapy;2023-10

2. Role of abatacept in the prevention of graft-versus-host disease: current perspectives;Therapeutic Advances in Hematology;2023-01

3. Targeted genome editing for the correction or alleviation of primary Immunodeficiencies;Progress in Molecular Biology and Translational Science;2021

4. Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation;Leukemia & Lymphoma;2017-12-04

5. The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease;Biomedicines;2017-11-29